Jane Street’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.9M | Buy |
175,100
+65,400
| +60% | +$14.2M | ﹤0.01% | 1547 |
|
|
2026
Q1 | $18.5M | Sell |
109,700
-7,900
| -7% | -$1.36M | ﹤0.01% | 1848 |
|
|
2025
Q4 | $21.5M | Buy |
117,600
+29,700
| +34% | +$4.15M | ﹤0.01% | 1566 |
|
|
2025
Q3 | $10.7M | Sell |
87,900
-35,800
| -29% | -$4.03M | ﹤0.01% | 2333 |
|
|
2025
Q2 | $12.9M | Sell |
123,700
-13,600
| -10% | -$1.44M | ﹤0.01% | 1873 |
|
|
2025
Q1 | $16M | Sell |
137,300
-258,100
| -65% | -$29.4M | ﹤0.01% | 1489 |
|
|
2024
Q4 | $33.5M | Buy |
395,400
+280,900
| +245% | +$25.8M | 0.01% | 910 |
|
|
2024
Q3 | $10.3M | Buy |
114,500
+42,500
| +59% | +$3.71M | ﹤0.01% | 1883 |
|
|
2024
Q2 | $5.8M | Sell |
72,000
-5,500
| -7% | -$407K | ﹤0.01% | 2755 |
|
|
2024
Q1 | $6.18M | Sell |
77,500
-51,400
| -40% | -$4.31M | ﹤0.01% | 2346 |
|
|
2023
Q4 | $10.3M | Buy |
128,900
+12,400
| +11% | +$829K | ﹤0.01% | 1922 |
|
|
2023
Q3 | $8.14M | Sell |
116,500
-69,700
| -37% | -$5.21M | ﹤0.01% | 2005 |
|
|
2023
Q2 | $13.4M | Sell |
186,200
-106,500
| -36% | -$7.86M | ﹤0.01% | 1605 |
|
|
2023
Q1 | $18.1M | Buy |
292,700
+39,600
| +16% | +$2.6M | 0.01% | 1079 |
|
|
2022
Q4 | $19.5M | Buy |
253,100
+71,500
| +39% | +$4.27M | 0.01% | 1030 |
|
|
2022
Q3 | $8.1M | Sell |
181,600
-120,600
| -40% | -$6.03M | ﹤0.01% | 1936 |
|
|
2022
Q2 | $11.6M | Buy |
302,200
+188,100
| +165% | +$5.95M | ﹤0.01% | 1572 |
|
|
2022
Q1 | $4.72M | Sell |
114,100
-522,500
| -82% | -$16.2M | ﹤0.01% | 3118 |
|
|
2021
Q4 | $24.1M | Buy |
636,600
+327,000
| +106% | +$12M | 0.01% | 1051 |
|
|
2021
Q3 | $10.2M | Buy |
309,600
+273,700
| +762% | +$10.7M | ﹤0.01% | 1779 |
|
|
2021
Q2 | $2.42M | Buy |
35,900
+18,400
| +105% | +$1.1M | ﹤0.01% | 3960 |
|
|
2021
Q1 | $991K | Sell |
17,500
-84,500
| -83% | -$5.94M | ﹤0.01% | 5474 |
|
|
2020
Q4 | $8.31M | Sell |
102,000
-31,000
| -23% | -$2.32M | ﹤0.01% | 1582 |
|
|
2020
Q3 | $9.48M | Sell |
133,000
-600
| -0.4% | -$46.8K | 0.01% | 1257 |
|
|
2020
Q2 | $11M | Sell |
133,600
-18,500
| -12% | -$1.42M | 0.01% | 1122 |
|
|
2020
Q1 | $8.95M | Buy |
152,100
+67,200
| +79% | +$5.48M | 0.01% | 824 |
|
|
2019
Q4 | $8.78M | Buy |
+84,900
| New | +$3.43M | 0.01% | 719 |
|
|
2019
Q2 | – | Sell |
-45,000
| Closed | -$640K | – | 5117 |
|
|
2019
Q1 | $640K | Buy |
+45,000
| New | +$418K | ﹤0.01% | 3372 |
|
Other funds holding AXSM
DTC
Jane Street's AXSM Position: Q2 2026 in Review
Jane Street increased its Axsome Therapeutics (AXSM) stake by 9,807% in Q2 2026, buying an estimated $86.7M and bringing the position to 403,995 shares worth $98.9M. The position accounts for 0.01% of the portfolio, ranked #944.
Jane Street first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Jane Street held 403,995 shares of Axsome Therapeutics worth $98.9M as of Q2 2026.
- Jane Street bought 399,917 Axsome Therapeutics shares in Q2 2026, an estimated $86.7M.
- Axsome Therapeutics made up 0.01% of Jane Street's portfolio in Q2 2026, its #944 holding.
- Jane Street first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.